High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.

Abstract excerpt

BACKGROUND: High tumor mutation burden is shown to be associated with a poor clinical outcome. As the tumor-derived fraction of circulating cell-free DNA (cfDNA) is shown to reflect the genetic spectrum of the tumor, we examined whether the mutation burden of cfDNA could be used to predict the clinical outcomes of early-stage breast cancer (BC) patients. METHODS: We selected a set of 79 Finnish early-stage BC...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell-Free Nucleic Acids
• Share to Breast Neoplasms